Portland biotech firm starts drug trials
A Portland biotechnology firm will soon conduct human trials on its drug designed to reduce the negative side effects and addictive properties of opiate pain medications.
Aiko Biotechnology was given approval earlier this month by the Food and Drug Administration to begin human testing on Aiko-150, which is intended to alleviate the drawbacks of drugs like OxyContin and Vicodin, according to the Portland Press Herald. Drugs must go through three phases of human testing before the company can apply with the FDA for permission to enter the market. Testing could be done as early as the end of 2010, and the drug could hit the market until as early as 2011.
The company was co-founded by Wolfgang Sadee, the chairman of the Dept. of Pharmacology at Ohio State University in Columbus, and Ed Bilsky, associate professor in the School of Pharmacology at the University of New England in Biddeford, the paper reported.
Most Recent
Most Recent
Comments